H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm adjusted operating expense forecasts and rolled its model forward. It expects positive Phase 3 myasthenia gravis data, citing the “impressive” Phase 2 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger
- Cartesian Therapeutics Advances mRNA Therapy Pipeline
- Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position
- Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
- Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year